Literature DB >> 15673288

Pathways to nephron loss starting from glomerular diseases-insights from animal models.

Wilhelm Kriz1, Michel LeHir.   

Abstract

Studies of glomerular diseases in animal models show that progression toward nephron loss starts with extracapillary lesions, whereby podocytes play the central role. If injuries remain bound within the endocapillary compartment, they will undergo recovery or be repaired by scaring. Degenerative, inflammatory and dysregulative mechanisms leading to nephron loss are distinguished. In addition to several other unique features, the dysregulative mechanisms leading to collapsing glomerulopathy are particular in that glomeruli and tubules are affected in parallel. In contrast, in degenerative and inflammatory diseases, tubular injury is secondary to glomerular lesions. In both of the latter groups of diseases, the progression starts in the glomerulus with the loss of the separation between the tuft and Bowman's capsule by forming cell bridges (parietal cells and/or podocytes) between the glomerular and the parietal basement membranes. Cell bridges develop into tuft adhesions to Bowman's capsule, which initiate the formation of crescents, either by misdirected filtration (proteinaceous crescents) or by epithelial cell proliferation (cellular crescents). Crescents may spread over the entire circumference of the glomerulus and, via the glomerulotubular junction, may extend onto the tubule. Two mechanisms concerning the transfer of a glomerular injury onto the tubulointerstitium are discussed: (1) direct encroachment of extracapillary lesions and (2) protein leakage into tubular urine, resulting in injury to the tubule and the interstitium. There is evidence that direct encroachment is the crucial mechanism. Progression of chronic renal disease is underlain by a vicious cycle which passes on the damage from lost and/or damaged nephrons to so far healthy nephrons. Presently, two mechanisms are discussed: (1) the loss of nephrons leads to compensatory mechanisms in the remaining nephrons (glomerular hypertension, hyperfiltration, hypertrophy) which increase their vulnerability to any further challenge (overload hypothesis); and (2) a proteinuric glomerular disease leads, by some way or another, to tubulointerstitial inflammation and fibrosis, accounting for the further deterioration of renal function (fibrosis hypothesis). So far, no convincing evidence has been published that in primary glomerular diseases fibrosis is harmful to healthy nephrons. The potential of glomerular injuries to regenerate or to be repaired by scaring is limited. The only option for extracapillary injuries with tuft adhesion is repair by formation of a segmental adherent scar (i.e., segmental glomerulosclerosis).

Entities:  

Mesh:

Year:  2005        PMID: 15673288     DOI: 10.1111/j.1523-1755.2005.67097.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  169 in total

1.  Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease.

Authors:  Akihiro Fukuda; Larysa T Wickman; Madhusudan P Venkatareddy; Yuji Sato; Mahboob A Chowdhury; Su Q Wang; Kerby A Shedden; Robert C Dysko; Jocelyn E Wiggins; Roger C Wiggins
Journal:  Kidney Int       Date:  2011-09-21       Impact factor: 10.612

2.  Diminished met signaling in podocytes contributes to the development of podocytopenia in transplant glomerulopathy.

Authors:  Putri A Agustian; Mario Schiffer; Wilfried Gwinner; Irini Schäfer; Katharina Theophile; Friedrich Modde; Clemens L Bockmeyer; Jana Traeder; Ulrich Lehmann; Anika Grosshennig; Hans H Kreipe; Verena Bröcker; Jan U Becker
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  PTEN loss defines a TGF-β-induced tubule phenotype of failed differentiation and JNK signaling during renal fibrosis.

Authors:  Rongpei Lan; Hui Geng; Aaron J Polichnowski; Prajjal K Singha; Pothana Saikumar; Donald G McEwen; Karen A Griffin; Robert Koesters; Joel M Weinberg; Anil K Bidani; Wilhelm Kriz; Manjeri A Venkatachalam
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-01

4.  Growth-dependent podocyte failure causes glomerulosclerosis.

Authors:  Akihiro Fukuda; Mahboob A Chowdhury; Madhusudan P Venkatareddy; Su Q Wang; Ryuzoh Nishizono; Tsukasa Suzuki; Larysa T Wickman; Jocelyn E Wiggins; Timothy Muchayi; Diane Fingar; Kerby A Shedden; Ken Inoki; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 10.121

Review 5.  The emerging role of the inflammasome in kidney diseases.

Authors:  Anthony Chang; Kichul Ko; Marcus R Clark
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-05       Impact factor: 2.894

Review 6.  Statins and proteinuria.

Authors:  Donald G Vidt
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 7.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

8.  Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats.

Authors:  Catherine Meyer-Schwesinger; Claudia Lange; Verena Bröcker; Putri Andina Agustian; Putri Andina Agustian; Ulrich Lehmann; Annette Raabe; Martina Brinkmeyer; Eiji Kobayashi; Mario Schiffer; Guntram Büsche; Hans H Kreipe; Friedrich Thaiss; Jan U Becker
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

9.  A mutation in the mouse Chd2 chromatin remodeling enzyme results in a complex renal phenotype.

Authors:  Concetta G A Marfella; Nils Henninger; Scott E LeBlanc; Namrata Krishnan; David S Garlick; Lawrence B Holzman; Anthony N Imbalzano
Journal:  Kidney Blood Press Res       Date:  2009-01-14       Impact factor: 2.687

10.  Conditionally immortalized human podocyte cell lines established from urine.

Authors:  Toru Sakairi; Yoshifusa Abe; Hiroshi Kajiyama; Linda D Bartlett; Lilian V Howard; Parmijit S Jat; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.